Immuneering On Track To First Patient Dosing For Phase 3 Atebimetinib Trial For First-Line Metastatic Pancreatic Cancer Patients; Completed End-Of-Phase 2 Interaction With FDA And Received Scientific Advice From EMA
Benzinga Newsdesk 10 months ago
BiotechNewsGeneral
– End-of-Phase 2 interactions with FDA complete; scientific advice received from EMA –– Company expects to dose first patient in global Phase 3 registrational trial, MAPKeeper 301, in mid-2026 –– Overall survival update
– End-of-Phase 2 interactions with FDA complete; scientific advice received from EMA –
– Company expects to dose first patient in global Phase 3 registrational trial, MAPKeeper 301, in mid-2026 –
– Overall survival update for Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients planned in coming weeks –